ARECOR THERAPEUTICS PLC

Regulatory Filings • May 21, 2024

National Storage Mechanism | Additional information

RNS Number : 1743P

Arecor Therapeutics PLC

21 May 2024

Arecor Therapeutics plc

("Arecor" or the "Group")

ARECOR TO HOST COMPANY AND KOL WEBINAR TODAY TO DISCUSS CLINICAL TRIAL RESULTS FOR ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN AT278 DEMONSTRATING SUPERIORITY IN PEOPLE WITH TYPE 2 DIABETES

·    Company will host a CEO and key opinion leader webinar at 14.30 BST

·    AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI

·    Confirms previous trial results in people with Type 1 diabetes, demonstrating AT278 can maintain fast and superior onset of action and glucose lowering profile irrespective of diabetes type and BMI

·    Enables delivery of a highly concentrated, low volume injection, offering more effective mealtime glucose control to meet growing unmet need in patients requiring high daily doses of insulin 

·    Creates potential to be the first, and only, ultra-concentrated (500 U/mL) ultra-rapid insulin product enabling miniaturisation of next-generation insulin pumps

Cambridge, UK, 21 May 2024 : Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it will host a CEO and key opinion leader webinar on the results of its Phase I clinical trial of that its ultra-concentrated, ultra-rapid acting insulin candidate, AT278. As announced on 20 May 2024, AT278 et all primary and secondary endpoints, and also demonstrated superiority to NovoRapid® and Humulin® R U-500, in a Phase I clinical trial in Type 2 diabetics with a high body mass index (BMI).

AT278 (500 U/mL) is an ultra-concentrated, ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection, even when delivered at a high concentration, and hence a lower injection volume. With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements.

Speakers at the webinar will be:

·    Professor Thomas Pieber, Principal Investigator for the ARE-278-104 clinical trial and Professor of Medicine, Head of the Division of Endocrinology and Metabolism and Chairman of the Department of Internal Medicine at Medical University of Graz, Austria

·    Sarah Howell, Chief Executive Officer of Arecor

To register to join the live webcast click  here  and to register for the conference line to ask questions click  here .

Please contact ICR Consilium for details on arecor@consilium-comms.com .

-ENDS-

For more information, please contact:

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: +44 (0) 1223 426060 Email: info@arecor.com
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: +44 (0) 20 7886 2500
WG Partners LLP (Financial Advisor)       Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang	Tel: +44 (0)203 705 9321
ICR Consilium
Chris Gardner, David Daley, Lindsey Neville	Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSEWFMSELSEDI